{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122792","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.565967+00:00","generated_at":"2026-05-30T03:59:06.094745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rapport Therapeutics Q3 net loss $17.5M; DPNP IND on clinical hold; cash $320.7M","bullets":["Net loss $17.5M vs $8.7M prior year; R&D expense $15.5M (up from $7.6M) driven by clinical development.","Cash, equivalents, and short-term investments $320.7M; expected to fund operations through end of 2026.","RAP-219 Phase 2a focal epilepsy trial on track; topline data expected mid-2025. MAD-2 and PET results Q1 2025.","FDA placed IND for diabetic peripheral neuropathic pain (DPNP) on clinical hold; focal epilepsy trial unaffected.","Appointed four new board members (Rob Perez, Raymond Sanchez, Paul Silva, Wendy Young); Jeff Tong resigned."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122792","json":"https://secwatch.observer/filing/0000950170-24-122792.json","markdown":"https://secwatch.observer/filing/0000950170-24-122792.md","text":"https://secwatch.observer/filing/0000950170-24-122792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024122792/0000950170-24-122792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024122792/rapp-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:59:06.094745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}